Akari Therapeutics plc ADS (NASDAQ: AKTX)
$1.2200
-0.0200 ( -0.81% ) 85.4K
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).